Visual outcomes in treated bacterial keratitis

Four years of prospective follow-up

Scott McClintic, Namperumalsamy V. Prajna, Muthiah Srinivasan, Jeena Mascarenhas, Prajna Lalitha, Revathi Rajaraman, Catherine E. Oldenburg, Kieran S. O'Brien, Kathryn J. Ray, Nisha R. Acharya, Thomas M. Lietman, Jeremy D. Keenan

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose. We described the change in visual acuity experienced by eyes successfully treated for bacterial keratitis. Methods. This was a prospective cohort study of a subset of study participants who had previously enrolled in the Steroids for Corneal Ulcers Trial (SCUT). All study participants had been diagnosed with culture-proven bacterial keratitis before enrollment in SCUT and subsequently were randomized to adjunctive topical corticosteroids or placebo. During SCUT, we monitored study participants at enrollment, 3 weeks, 3 months, and 12 months. We invited a subset to complete a comprehensive eye examination approximately 4 years after enrollment in SCUT. Certified refractionists assessed best spectacle-corrected visual acuity (BSCVA) using the same protocol at each study visit. Results. We examined 50 SCUT participants at 4 years after enrollment. Among those in this cohort, mean logMAR BSCVA at enrollment was 0.85 (Snellen equivalent, 20/160; 95% confidence interval [CI], 0.71-0.99). On average, visual acuity improved by 2.9 logMAR lines from enrollment to 3 weeks (P <0.001), 1.2 lines from 3 weeks to 3 months (P = 0.002), and 0.8 lines from 3 to 12 months (P = 0.01). The BSCVA did not change significantly between 12 months and 4 years (0.04-line improvement, P = 0.88). After controlling for visual acuity at enrollment, BSCVA was not significantly different between the corticosteroid and placebo groups at 4 years (P = 0.53). Conclusions. Cases of bacterial keratitis may continue to demonstrate improvements in visual acuity up to 12 months following diagnosis, but further improvements are unlikely. These findings may guide the appropriate timing of surgical intervention in these patients. (ClinicalTrials.gov number, NCT00324168.)

Original languageEnglish (US)
Pages (from-to)2935-2940
Number of pages6
JournalInvestigative Ophthalmology and Visual Science
Volume55
Issue number5
DOIs
StatePublished - Mar 11 2014
Externally publishedYes

Fingerprint

Keratitis
Visual Acuity
Corneal Ulcer
Steroids
Adrenal Cortex Hormones
Placebos
Cohort Studies
Prospective Studies
Confidence Intervals

Keywords

  • Clinical trial
  • Keratitis
  • Long-term
  • Outcomes
  • Prospective
  • Visual acuity

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

McClintic, S., Prajna, N. V., Srinivasan, M., Mascarenhas, J., Lalitha, P., Rajaraman, R., ... Keenan, J. D. (2014). Visual outcomes in treated bacterial keratitis: Four years of prospective follow-up. Investigative Ophthalmology and Visual Science, 55(5), 2935-2940. https://doi.org/10.1167/iovs.14-13980

Visual outcomes in treated bacterial keratitis : Four years of prospective follow-up. / McClintic, Scott; Prajna, Namperumalsamy V.; Srinivasan, Muthiah; Mascarenhas, Jeena; Lalitha, Prajna; Rajaraman, Revathi; Oldenburg, Catherine E.; O'Brien, Kieran S.; Ray, Kathryn J.; Acharya, Nisha R.; Lietman, Thomas M.; Keenan, Jeremy D.

In: Investigative Ophthalmology and Visual Science, Vol. 55, No. 5, 11.03.2014, p. 2935-2940.

Research output: Contribution to journalArticle

McClintic, S, Prajna, NV, Srinivasan, M, Mascarenhas, J, Lalitha, P, Rajaraman, R, Oldenburg, CE, O'Brien, KS, Ray, KJ, Acharya, NR, Lietman, TM & Keenan, JD 2014, 'Visual outcomes in treated bacterial keratitis: Four years of prospective follow-up', Investigative Ophthalmology and Visual Science, vol. 55, no. 5, pp. 2935-2940. https://doi.org/10.1167/iovs.14-13980
McClintic S, Prajna NV, Srinivasan M, Mascarenhas J, Lalitha P, Rajaraman R et al. Visual outcomes in treated bacterial keratitis: Four years of prospective follow-up. Investigative Ophthalmology and Visual Science. 2014 Mar 11;55(5):2935-2940. https://doi.org/10.1167/iovs.14-13980
McClintic, Scott ; Prajna, Namperumalsamy V. ; Srinivasan, Muthiah ; Mascarenhas, Jeena ; Lalitha, Prajna ; Rajaraman, Revathi ; Oldenburg, Catherine E. ; O'Brien, Kieran S. ; Ray, Kathryn J. ; Acharya, Nisha R. ; Lietman, Thomas M. ; Keenan, Jeremy D. / Visual outcomes in treated bacterial keratitis : Four years of prospective follow-up. In: Investigative Ophthalmology and Visual Science. 2014 ; Vol. 55, No. 5. pp. 2935-2940.
@article{a5d141a241c945358e1c49701e8054c3,
title = "Visual outcomes in treated bacterial keratitis: Four years of prospective follow-up",
abstract = "Purpose. We described the change in visual acuity experienced by eyes successfully treated for bacterial keratitis. Methods. This was a prospective cohort study of a subset of study participants who had previously enrolled in the Steroids for Corneal Ulcers Trial (SCUT). All study participants had been diagnosed with culture-proven bacterial keratitis before enrollment in SCUT and subsequently were randomized to adjunctive topical corticosteroids or placebo. During SCUT, we monitored study participants at enrollment, 3 weeks, 3 months, and 12 months. We invited a subset to complete a comprehensive eye examination approximately 4 years after enrollment in SCUT. Certified refractionists assessed best spectacle-corrected visual acuity (BSCVA) using the same protocol at each study visit. Results. We examined 50 SCUT participants at 4 years after enrollment. Among those in this cohort, mean logMAR BSCVA at enrollment was 0.85 (Snellen equivalent, 20/160; 95{\%} confidence interval [CI], 0.71-0.99). On average, visual acuity improved by 2.9 logMAR lines from enrollment to 3 weeks (P <0.001), 1.2 lines from 3 weeks to 3 months (P = 0.002), and 0.8 lines from 3 to 12 months (P = 0.01). The BSCVA did not change significantly between 12 months and 4 years (0.04-line improvement, P = 0.88). After controlling for visual acuity at enrollment, BSCVA was not significantly different between the corticosteroid and placebo groups at 4 years (P = 0.53). Conclusions. Cases of bacterial keratitis may continue to demonstrate improvements in visual acuity up to 12 months following diagnosis, but further improvements are unlikely. These findings may guide the appropriate timing of surgical intervention in these patients. (ClinicalTrials.gov number, NCT00324168.)",
keywords = "Clinical trial, Keratitis, Long-term, Outcomes, Prospective, Visual acuity",
author = "Scott McClintic and Prajna, {Namperumalsamy V.} and Muthiah Srinivasan and Jeena Mascarenhas and Prajna Lalitha and Revathi Rajaraman and Oldenburg, {Catherine E.} and O'Brien, {Kieran S.} and Ray, {Kathryn J.} and Acharya, {Nisha R.} and Lietman, {Thomas M.} and Keenan, {Jeremy D.}",
year = "2014",
month = "3",
day = "11",
doi = "10.1167/iovs.14-13980",
language = "English (US)",
volume = "55",
pages = "2935--2940",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "5",

}

TY - JOUR

T1 - Visual outcomes in treated bacterial keratitis

T2 - Four years of prospective follow-up

AU - McClintic, Scott

AU - Prajna, Namperumalsamy V.

AU - Srinivasan, Muthiah

AU - Mascarenhas, Jeena

AU - Lalitha, Prajna

AU - Rajaraman, Revathi

AU - Oldenburg, Catherine E.

AU - O'Brien, Kieran S.

AU - Ray, Kathryn J.

AU - Acharya, Nisha R.

AU - Lietman, Thomas M.

AU - Keenan, Jeremy D.

PY - 2014/3/11

Y1 - 2014/3/11

N2 - Purpose. We described the change in visual acuity experienced by eyes successfully treated for bacterial keratitis. Methods. This was a prospective cohort study of a subset of study participants who had previously enrolled in the Steroids for Corneal Ulcers Trial (SCUT). All study participants had been diagnosed with culture-proven bacterial keratitis before enrollment in SCUT and subsequently were randomized to adjunctive topical corticosteroids or placebo. During SCUT, we monitored study participants at enrollment, 3 weeks, 3 months, and 12 months. We invited a subset to complete a comprehensive eye examination approximately 4 years after enrollment in SCUT. Certified refractionists assessed best spectacle-corrected visual acuity (BSCVA) using the same protocol at each study visit. Results. We examined 50 SCUT participants at 4 years after enrollment. Among those in this cohort, mean logMAR BSCVA at enrollment was 0.85 (Snellen equivalent, 20/160; 95% confidence interval [CI], 0.71-0.99). On average, visual acuity improved by 2.9 logMAR lines from enrollment to 3 weeks (P <0.001), 1.2 lines from 3 weeks to 3 months (P = 0.002), and 0.8 lines from 3 to 12 months (P = 0.01). The BSCVA did not change significantly between 12 months and 4 years (0.04-line improvement, P = 0.88). After controlling for visual acuity at enrollment, BSCVA was not significantly different between the corticosteroid and placebo groups at 4 years (P = 0.53). Conclusions. Cases of bacterial keratitis may continue to demonstrate improvements in visual acuity up to 12 months following diagnosis, but further improvements are unlikely. These findings may guide the appropriate timing of surgical intervention in these patients. (ClinicalTrials.gov number, NCT00324168.)

AB - Purpose. We described the change in visual acuity experienced by eyes successfully treated for bacterial keratitis. Methods. This was a prospective cohort study of a subset of study participants who had previously enrolled in the Steroids for Corneal Ulcers Trial (SCUT). All study participants had been diagnosed with culture-proven bacterial keratitis before enrollment in SCUT and subsequently were randomized to adjunctive topical corticosteroids or placebo. During SCUT, we monitored study participants at enrollment, 3 weeks, 3 months, and 12 months. We invited a subset to complete a comprehensive eye examination approximately 4 years after enrollment in SCUT. Certified refractionists assessed best spectacle-corrected visual acuity (BSCVA) using the same protocol at each study visit. Results. We examined 50 SCUT participants at 4 years after enrollment. Among those in this cohort, mean logMAR BSCVA at enrollment was 0.85 (Snellen equivalent, 20/160; 95% confidence interval [CI], 0.71-0.99). On average, visual acuity improved by 2.9 logMAR lines from enrollment to 3 weeks (P <0.001), 1.2 lines from 3 weeks to 3 months (P = 0.002), and 0.8 lines from 3 to 12 months (P = 0.01). The BSCVA did not change significantly between 12 months and 4 years (0.04-line improvement, P = 0.88). After controlling for visual acuity at enrollment, BSCVA was not significantly different between the corticosteroid and placebo groups at 4 years (P = 0.53). Conclusions. Cases of bacterial keratitis may continue to demonstrate improvements in visual acuity up to 12 months following diagnosis, but further improvements are unlikely. These findings may guide the appropriate timing of surgical intervention in these patients. (ClinicalTrials.gov number, NCT00324168.)

KW - Clinical trial

KW - Keratitis

KW - Long-term

KW - Outcomes

KW - Prospective

KW - Visual acuity

UR - http://www.scopus.com/inward/record.url?scp=84899737056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899737056&partnerID=8YFLogxK

U2 - 10.1167/iovs.14-13980

DO - 10.1167/iovs.14-13980

M3 - Article

VL - 55

SP - 2935

EP - 2940

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 5

ER -